UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2031) 2031
Newsletter (29) 29
Book Chapter (18) 18
Dissertation (7) 7
Newspaper Article (6) 6
Magazine Article (2) 2
Reference (2) 2
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fludarabine (1829) 1829
science & technology (1448) 1448
life sciences & biomedicine (1406) 1406
humans (1297) 1297
vidarabine - analogs & derivatives (986) 986
hematology (894) 894
male (831) 831
female (783) 783
oncology (756) 756
middle aged (713) 713
adult (568) 568
aged (559) 559
vidarabine - administration & dosage (464) 464
transplantation (408) 408
vidarabine - therapeutic use (369) 369
leukemia, lymphocytic, chronic, b-cell - drug therapy (358) 358
chronic lymphocytic leukemia (350) 350
treatment outcome (344) 344
antineoplastic combined chemotherapy protocols - therapeutic use (321) 321
cyclophosphamide (314) 314
rituximab (275) 275
leukemia (273) 273
immunology (258) 258
vidarabine - adverse effects (249) 249
antineoplastic agents - therapeutic use (246) 246
cancer (234) 234
chemotherapy (223) 223
care and treatment (215) 215
stem cells (215) 215
transplantation conditioning - methods (207) 207
hematopoietic stem cells (204) 204
adolescent (198) 198
stem cell transplantation (183) 183
research (180) 180
aged, 80 and over (179) 179
patients (173) 173
dosage and administration (166) 166
antineoplastic agents (162) 162
busulfan (162) 162
health aspects (160) 160
cyclophosphamide - administration & dosage (158) 158
retrospective studies (158) 158
disease-free survival (156) 156
vidarabine - pharmacology (155) 155
apoptosis (154) 154
antineoplastic combined chemotherapy protocols - adverse effects (152) 152
biophysics (152) 152
transplantation, homologous (147) 147
antimitotic agents (146) 146
remission induction (143) 143
survival rate (142) 142
drug therapy (140) 140
hematopoietic stem cell transplantation (140) 140
medicine & public health (136) 136
prognosis (134) 134
lymphoma (128) 128
risk factors (127) 127
bone marrow (124) 124
child (123) 123
cll (122) 122
leukemia, lymphocytic, chronic, b-cell - pathology (120) 120
analysis (118) 118
chronic lymphatic leukemia (117) 117
antineoplastic agents - pharmacology (116) 116
survival analysis (116) 116
toxicity (116) 116
young adult (116) 116
antineoplastic agents - adverse effects (114) 114
hematopoietic stem cell transplantation - methods (114) 114
cladribine (112) 112
antineoplastic combined chemotherapy protocols - administration & dosage (111) 111
recurrence (111) 111
survival (109) 109
pharmacology & pharmacy (106) 106
animals (105) 105
cytarabine (105) 105
follow-up studies (105) 105
hematology, oncology and palliative medicine (100) 100
alemtuzumab (98) 98
hemopoiesis (93) 93
patient outcomes (90) 90
acute myeloid leukemia (89) 89
antineoplastic agents - administration & dosage (88) 88
child, preschool (85) 85
leukemia, lymphocytic, chronic, b-cell - mortality (84) 84
chronic lymphocytic leukaemia (83) 83
hemic and lymphatic diseases (83) 83
mortality (83) 83
lymphoma, non-hodgkin - drug therapy (81) 81
transplantation conditioning (80) 80
dose-response relationship, drug (78) 78
transplants & implants (78) 78
hematopoietic stem cell transplantation - adverse effects (77) 77
lymphocytes (77) 77
melphalan (77) 77
apoptosis - drug effects (76) 76
clinical trials (76) 76
graft-versus-host reaction (76) 76
immunosuppressive agents - therapeutic use (75) 75
busulfan - administration & dosage (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2017) 2017
Polish (17) 17
French (14) 14
Russian (10) 10
Chinese (9) 9
German (9) 9
Japanese (8) 8
Spanish (8) 8
Czech (7) 7
Portuguese (5) 5
Italian (4) 4
Korean (4) 4
Slovak (3) 3
Turkish (3) 3
Hungarian (2) 2
Romanian (2) 2
Persian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 03/2012, Volume 30, Issue 9, pp. 980 - 988
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 2018, Volume 23, Issue 45, pp. 7003 - 7024
Background: The selective expression of non-human genes in tumor tissue to activate non-toxic compounds (Gene Directed Enzyme Prodrug Therapy, GDEPT) is a... 
Purine nucleoside phosphorylase | Fludarabine | GDEPT | 2-fluoroadenine | Anticancer drugs | Gedeptin | Gene therapy | 6-methylpurine | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1647 - 1655
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 2018, Volume 24, Issue 11, pp. 1224 - 1240
Background: Unintentional passive diffusion of conventional small molecular weight pharmaceuticals across intact membranes of normal healthy cells in tissues... 
Anti-IGF-1R | Anti-EGFR | Anti-neoplastic cytotoxic potency | Dexamethasone | Fludarabine | Gemcitabine | Selective “targeted” delivery | Covalent immunopharmaceuticals | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 31 - 42
Journal Article
Haematologica (Roma), ISSN 1592-8721, 05/2010, Volume 95, Issue 6, pp. 976 - 982
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 04/2019, Volume 12, Issue 1, pp. 44 - 44
BackgroundLimited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with... 
Conditioning regimen | Fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) | Thiotepa-busulfan-fludarabine (TBF) | Active disease | Allogeneic transplantation | Sibling donor (MSD) | Fludarabine-treosulfan (FT) | Unrelated donor (UD) | Acute myeloid leukemia (AML) | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Thiotepa - therapeutic use | Busulfan - analogs & derivatives | Busulfan - pharmacology | Busulfan - therapeutic use | Leukemia, Myeloid, Acute - pathology | Europe | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Young Adult | Vidarabine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Retrospective Studies | Thiotepa - pharmacology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Cyclophosphamide | Relapse | Care and treatment | Oncology, Experimental | Mortality | Bone marrow | Transplantation | Research | Health aspects | Cancer | Diseases | Graft-versus-host reaction | Transplants & implants | Myeloid leukemia | Leukemia | Radiation | Serology | Treosulfan | Survival | Studies | Chemotherapy | Fludarabine | Thymocytes | Globulins | Stem cells | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article